Novo Nordisk Files for CagriSema Approval

December 31, 20251 Min Read

Novo Nordisk Files for CagriSema Approval

Published: 31 Dec 2025, 08:58 IST

Novo Nordisk has filed for approval of its obesity drug CagriSema.
Internal hub

Previous ArticleNovo Nordisk’s Oral Wegovy Gains FDA Approval

Next Article FDA Places Hold on Merck and Daiichi’s ADC Trial